Full metadata record
DC FieldValueLanguage
dc.creatorPaiva, B. (Bruno)-
dc.creatorCedena, M.T. (María Teresa)-
dc.creatorPuig, N. (Noemí)-
dc.creatorArana, P. (Paula)-
dc.creatorVidriales, M.B. (María Belén)-
dc.creatorCordón, L. (Lourdes)-
dc.creatorMontero, J. (Juan)-
dc.creatorGutierrez, N.C. (Norma C.)-
dc.creatorMartin-Ramos, M.L. (Maria Luisa)-
dc.creatorMartínez-López, J. (Joaquín)-
dc.creatorOcio, E.M. (Enrique M.)-
dc.creatorHernandez, M.T. (Miguel Teodoro)-
dc.creatorTeruel, A.I. (Ana Isabel)-
dc.creatorRosiñol, L. (Laura)-
dc.creatorEcheveste, M.A. (Maria Asuncion)-
dc.creatorMartínez, R. (Rafael)-
dc.creatorGironella, M. (Mercedes)-
dc.creatorOriol, A. (Albert)-
dc.creatorCabrera, C. (Carmen)-
dc.creatorMartin, J. (Jesus)-
dc.creatorBargay, J. (Joan)-
dc.creatorEncinas, C. (Cristina)-
dc.creatorGonzalez, Y. (Yolanda)-
dc.creatorDongen, J.J.M. (Jacques J. M.) van-
dc.creatorOrfao, A. (Alberto)-
dc.creatorBladé, J. (Joan)-
dc.creatorMateos, M.V. (María Victoria)-
dc.creatorLahuerta, J.J. (Juan José)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.date.accessioned2018-05-09T08:20:38Z-
dc.date.available2018-05-09T08:20:38Z-
dc.date.issued2016-
dc.identifier.citationPaiva, B. (Bruno); Cedena, M.T. (María Teresa); Puig, N. (Noemí); et al. "Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma". Blood. 127 (25), 2016,es
dc.identifier.issn0006-4971-
dc.identifier.urihttps://hdl.handle.net/10171/52177-
dc.description.abstractThe value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible than elderly patients. Since an optimal balance between treatment efficacy and toxicity is of utmost importance in elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used 2nd generation 8-color multiparameter-flow-cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study, The transition from 1st to 2nd generation MFC resulted in increased sensitivity, and allowed to identify three patient groups according to MRD levels: MRD-negative (<10-5; n=54, 34%), MRD-positive between <10-4 and ≥10-5 (n=20, 12%), and MRD-positive ≥10-4 (n=88, 54%). MRD status was an independent prognostic factor for time-to progression (-TTP- HR:2.7; P=.007) and overall survival (-OS- HR:3.1; P=.04) with significant benefit for MRD-negative patients (median TTP not reached, 70% OS at 3-years), and similar poorer outcomes for cases with MRD levels between <10-4 and ≥10-5 vs ≥10-4 (both median TTP of 15 months; 63% and 55% OS at 3-years). Furthermore, MRD-negativity significantly improved TTP of patients >75-years (HR:4.8; P<.001), and those with high-risk cytogenetics (HR:12.6; P=.01). Using 2nd generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate and favorable outcome (25%, 61% and 100% OS at 3-years; P=.01); the later patients being characterized by an increased compartment of mature B-cells. Our results show that similarly to transplant-candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM, irrespectively of patients’ age and cytogenetic risk.es_ES
dc.description.sponsorshipThis study was supported by Cooperative Research Thematic Network grants RD12/0036/0058, RD12/0036/0048, RD12/0036/ 0046, and RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdireccion General de Investigaci ́ on Sanitaria ́ (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/ 01370; PI13/01469, PI14/01867, G03/136; Sara Borrell: CD13/ 00340 and CD12/00540); and Asociacion Española Contra el ́ Cancer (GCB120981SAN). The study was also supported interna- ́ tionally by the Black Swan Research Initiative of the International Myeloma Foundation and a European Research Council 2015 starting grant.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society of Hematologyes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/ERC/680200-MYELOMANEXT-
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectMaterias Investigacion::Ciencias de la Salud::Hematologíaes_ES
dc.titleMinimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myelomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://www.bloodjournal.org/content/early/2016/04/26/blood-2016-03-705319es_ES
dc.identifier.doi10.1182/blood-2016-03-705319-

Files in This Item:
Thumbnail
File
BLOOD-2016-705319.pdf
Description
Size
148.91 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.